A Device Strategy-Matched Comparison Analysis among Different Intermacs Profiles: A Single Center Experience

Raphael Caraffa 1,†, Jonida Bejko 1,†, Massimiliano Carrozzini 1, Olimpia Bifulco 1, Vincenzo Tarzia 1, Giulia Lorenzoni 2, Daniele Bottigliengo 2, Dario Gregori 2, Chiara Castellani 3, Tomaso Bottio 1,*‡, Annalisa Angelini 3‡ and Gino Gerosa 1‡

1 Cardiac Surgery Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, 35128 Padova, Italy
2 Unit of Biostatistics, Epidemiology and Public Health, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, 35128 Padova, Italy
3 Cardiovascular Pathology, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, 35128 Padova, Italy
* Correspondence: tbottio@gmail.com; Tel.: +39-0498-212-410; Fax: +39-0498-212-409
† These authors contributed equally to this work.
‡ These authors contributed equally to this work.

Abstract: Background: The present study evaluates outcomes of LVAD patients, taking into account the device strategy and the INTERMACS profile. Methods: We included 192 LVAD-patients implanted between January 2012 and May 2021. The primary and secondary end-points were survival and major adverse events between Profiles 1–3 vs. Profile 4, depending on implantation strategies (Bridge-to-transplant-BTT; Bridge-to-candidacy-BTC; Destination-Therapy-DT). Results: The overall survival was 67% (61–75) at 12 months and 61% (54–70) at 24 months. Profile 4 patients showed significantly higher survival (p = 0.018). Incidences of acute right-ventricular-failure (RVF) (p = 0.046), right-ventricular-assist-device (RVAD) implantation (p = 0.015), and continuous-venovenous-hemofiltration (CVVH) (p = 0.006) were higher in Profile 1–3 patients, as well as a longer intensive care unit stays (p = 0.050) and in-hospital-mortality (p = 0.012). Twelve-month and 24-month survival rates were higher in the BTT rather than in BTC (log-rank = 0.410; log-rank = 0.120) and in DT groups (log-rank = 0.046). In the BTT group, Profile 1–3 patients had a higher need for RVAD support (p = 0.042). Conclusions: LVAD implantation in elective patients was associated with better survival and lower complications incidence. LVAD implantation in BTC patients has to be considered before their conditions deteriorate. DT should be addressed to elective patients in order to guarantee acceptable results.

Keywords: mechanical circulatory support; left ventricular assist device; heart failure; device strategy

1. Introduction

End-stage heart failure (ESHF) is a major healthcare issue. Heart transplant (HT) represents the gold standard treatment, but it is limited by the shortage of available organs [1–4]. The results with LVAD implantation have significantly improved thanks to the advancement in technologies [5–11]. The enrolment of ambulatory patients in these programs is still under debate. In a recent prospective study of ambulatory patients with ESHF, LVAD therapy was associated with improved quality of life and patient’s functional capacity when compared with the optimal medical management [12]. The present study aims at evaluating the outcomes of LVAD patients, taking into account the device strategy and the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) profile.
2. Methods

2.1. Study Population

We designed a retrospective, observational, single center study including all ESHF patients who underwent LVAD implantation in our institution (University of Padua, Italy) between January 2012 and May 2021. Exclusion criteria were pediatric patients (younger than 18 years old), and the implantation of biventricular assist devices (BiVAD) or total artificial heart (TAH). Baseline demographics, clinical characteristics, laboratory data, echocardiography, and hemodynamic status were assessed at hospitalization. Intraoperative and postoperative data were prospectively collected, and patients were classified according to the INTERMACS profile definitions. We considered the device strategy assigned prior to implantation based on the intention to treat: bridge to transplantation (BTT), bridge to candidacy (BTC), and destination therapy (DT). Concerning the INTERMACS level, patients were assigned to two different groups: “critically ill” patients, including INTERMACS profiles 1–3, and “elective” patients, including the INTERMACS profile 4. All patients were followed up until death on device, orthotopic HT, or day of last observation, set on 30 April 2022.

2.2. Study Outcomes

The primary end-point of the study was overall survival. The secondary end-point was the onset of major adverse events.

2.3. Definitions

The INTERMACS Profile was defined according to the Interagency Registry for Mechanically Assisted Circulatory Support [6] and assigned to each patient by a dedicated team of cardiologists and cardiac surgeons before the implantation. The BTT strategy was based on the possibility of active insertion on the waiting list after the implantation. A patient was considered to be on a BTC when pulmonary resistances were high but reversible and represented a relative contraindication to transplantation. Other causes of BTC were malignancy on diagnostic definition, substance addictions, and obesity. In our cent, LVAD as a DT was reserved for patients eligible for mechanical support but too old to be transplanted (older than 70 years old) or with contraindication to transplantation, such as confirmed neoplasia.

Major outcomes were defined in accordance with the latest consensus statement on adverse events definitions of mechanical circulatory support [13]. Acute right ventricular failure (RVF) included early acute RVF and early post-implant RVF. Early acute RVF was defined by the need for implantation of a temporary or durable RVAD (including ECMO) concomitant with LVAD implantation (before the patient leaves the operating room). Early post-implant RVF was defined by the need for implantation of an RVAD within 30 days following implantation or failure to wean from inotropic support or inhaled nitric oxide within 14 days following implantation in the presence of clinical findings of RVF. Late RVF was represented by the need for implantation of an RVAD greater than 30 days after LVAD implantation or hospitalization greater than 30 days, which requires intravenous diuretic or inotropic support for at least 72 h and associated with RVF symptoms.

2.4. LVAD Management

Indications for LVAD implantation followed the latest European Society of Cardiology, European Association for Cardio-Thoracic Surgery, and ISHLT guidelines [1–4]. All patients of our cohort were assisted with a continuous-flow generation LVAD. Devices used were: Jarvik 2000 FlowMaker™ VAD (Jarvik Heart Inc., New York, NY, USA), HeartWare HVAD™ System (Medtronic, Dublin, Ireland), and HeartMate 3™ LVAD (Abbott, Chicago, IL, USA). The implant was performed through a classic median longitudinal sternotomy or through minimally invasive approaches [14–16]. Intraoperative evaluation of the right ventricular function was crucial. Difficult weaning from cardiopulmonary bypass, hemodynamic compromise despite high doses of inotropes, and echocardiographic evidence of right
ventricular distention recommended an RVAD implantation. Depending on the era, RVAD setting was central, using a Levitronix CentriMag (Levitronix LLC, Waltham, MA, USA) support, or percutaneous, TandemLife Protek Duo (TPD; TandemLife, Pittsburgh, PA, USA). At the end of the hospital stay, patients were referred to specialized cardiac rehabilitation units and then periodically evaluated in our dedicated outpatient clinic.

2.5. Statistical Analysis

Continuous variables are presented as median and interquartile range (IQR). The Student’s t-test for unpaired data or the Mann-Whitney U test was used to compare parametric and non-parametric continuous variables respectively (normal distribution was assessed by the Kolmogorov-Smirnov test). Categorical variables were presented as numbers and percentages. \( X^2 \) analysis or the Fisher exact test was used to compare categorical variables where appropriate. A two-sided \( p \)-value of less than 0.05 was considered significant. Survival estimates were provided with the Kaplan–Meier method; data are represented as percentages and 95% confidence interval. Log-rank is reported and considered significant when less than 0.05. Patients were censored in case of HT or last follow-up available. A competing risk analysis was conducted in the BTT cohort to estimate the cumulative risk of a patient moving into one of three exclusive events: alive and on waiting list, HT, and death. All statistical analyses were performed using R software 3.3.5 [17] and SPSS software version 20 (IBM Corp., Armonk, NY, USA).

2.6. Study Oversight

Informed consent was obtained to participate in this study. Notably, the use of data for scientific and research purposes is already included in the surgical informed consent agreements. The local Institutional Review Board approved the study design, consent process, and review and analysis of the data (IBR number 48398/21). We also guarantee the respect of anonymity and professional secrecy and use the collected data and the statistical analysis solely for scientific purposes granted in accordance with the law in force (GDPR).

3. Results

3.1. Baseline Characteristics and LVAD Implantation

Table 1 summarizes all the baseline demographics and clinical characteristics, preoperative laboratory, and echocardiogram parameters. 192 patients underwent LVAD implantation for ESHF. The median age was 62 years (54–67), and 87% of them were males. Forty-five patients (23%) were classified as INTERMACS Profile 4. The most frequent device strategy adopted was BTT in 79 patients (41%), followed by BTC in 58 (30%) and DT in 55 (29%). Comparing the critically ill patients (147) to the elective patients (45), the sicker tended to be younger (\( p = 0.001 \)) and more often required continuous dialysis treatment before implantation (\( p = 0.008 \)). Moreover, their precarious hemodynamic condition was remarked by end-organ parameters such as higher BNP (\( p = 0.050 \)), lower haemoglobin levels (\( p = 0.040 \)) and sodium levels (\( p = 0.048 \)), hepatic suffering with higher levels of AST (\( p = 0.002 \)), ALT (\( p = 0.003 \)) and bilirubin (\( p < 0.001 \)), and higher C-reactive protein (\( p < 0.001 \)). The data regarding LVAD implantation are collected in Table 2.

3.2. Overall Results

The pertinent data are represented in Table 3. Profiles 1–3 patients showed a higher incidence of acute right ventricular failure (RVF) (\( p = 0.046 \)), RVAD implantation (\( p = 0.015 \)), and acute kidney failure requiring dialysis (\( p = 0.006 \)). The most frequent adverse event observed was bleeding (37%), requiring at least one surgical revision in almost all cases (85%), followed by cerebral events in 24% of the population, mainly ischemic (60%), with 40% mortality. Bowel complications were present in 13% of the patients, but less than 3% died due to intestinal ischemia.
Table 1. Baseline characteristics, preoperative labs, and echocardiogram parameters of overall \((n = 192)\), INTERMACS Profile 1–3 \((n = 147)\) and Profile 4 \((n = 45)\) patients.

| Baseline Characteristic | Overall \((n = 192)\) | Profile 1–3 \((n = 147)\) | Profile 4 \((n = 45)\) | \(p\) |
|-------------------------|----------------------|--------------------------|----------------------|-------|
| Age at Implant          | 62.4 (54.5–66.9)     | 60.6 (52.6–66.2)         | 64.9 (61.3–68.7)     | 0.001 |
| Gender (male)           | 167 (87%)            | 124 (84.4%)              | 43 (95.6%)           | 0.073 |
| Cardiac Diagnosis       |                      |                          |                      | 0.389 |
| DCM                     | 86 (44.8%)           | 69 (49.6%)               | 17 (37.8%)           |       |
| IHD                     | 94 (49.0%)           | 68 (46.3%)               | 26 (57.8%)           |       |
| Other                   | 12 (6.2%)            | 10 (6.8%)                | 2 (4.4%)             |       |
| INTERMACS class         |                      |                          |                      |       |
| 1                       | 60 (31.2%)           |                          |                      |       |
| 2                       | 27 (14.1%)           |                          |                      |       |
| 3                       | 60 (31.2%)           |                          |                      |       |
| 4                       | 45 (23.4%)           |                          |                      |       |
| Device Strategy         |                      |                          |                      | 0.898 |
| Bridge to transplantation (BTT) | 79 (41.1%)   | 58 (39.5%)               | 21 (46.7%)           |       |
| Bridge to candidacy (BTC) | 58 (30.2%)         | 50 (34.0%)               | 8 (17.7%)            |       |
| Destination therapy (DT) | 55 (28.7%)         | 39 (26.5%)               | 16 (35.6%)           |       |
| Type of device          |                      |                          |                      | 0.528 |
| Jarvik                  | 62 (32.3%)           | 45 (30.6%)               | 17 (37.8%)           |       |
| HVAD                    | 54 (28.1%)           | 44 (29.9%)               | 10 (22.2%)           |       |
| Heart Mate 3            | 76 (39.6%)           | 58 (39.5%)               | 18 (40.0%)           |       |
| Smoker                  | 80 (41.7%)           | 61 (41.5%)               | 19 (42.2%)           | 0.931 |
| Dyslipidaemia           | 95 (49.5%)           | 66 (44.9%)               | 29 (64.4%)           | 0.027 |
| Hypertension            | 109 (56.8%)          | 78 (53.1%)               | 31 (68.9%)           | 0.085 |
| AF preop                | 73 (38.0%)           | 56 (31.3%)               | 17 (37.8%)           | 0.969 |
| Cancer                  | 17 (8.9%)            | 14 (9.5%)                | 3 (6.7%)             | 0.766 |
| Diabetes                | 58 (30.2%)           | 43 (29.3%)               | 15 (33.3%)           | 0.584 |
| Peripheral vascular disease | 50 (26.0%)       | 32 (21.8%)               | 18 (40.0%)           | 0.020 |
| COPD                    | 17 (8.9%)            | 13 (8.8%)                | 4 (8.9%)             | 0.993 |
| BSA (m²)                | 1.88 (1.77–2.00)     | 1.88 (1.74–2.00)         | 1.90 (1.80–1.99)     | 0.573 |
| ICD                     | 129 (67.2%)          | 88 (59.9%)               | 41 (91.1%)           | <0.001 |
| Redo                    | 30 (15.6%)           | 20 (13.6%)               | 10 (22.2%)           | 0.167 |
| Cardiac Index (L/min/m²) | 2.00 (1.95–2.05)   | 1.98 (1.95–2.00)         | 2.00 (1.92–2.05)     | 0.040 |
| Preop vO2 Peak (mL/min/m²) | 11.0 (9.0–12.0)    | 11.0 (9.0–12.0)          | 11.0 (10.5–12.5)     | 0.136 |
| Preop CVVH              | 18 (9.4%)            | 18 (12.2%)               | 0 (0.0%)             | 0.008 |
| Preop CVVH days         | 5.5 (3.8–8.5)        | 5.5 (3.8–8.5)            |                      |       |
| Preop ECOM              | 48 (25.0%)           |                          |                      |       |
| Days                    | 5.0 (2.0–10.0)       |                          |                      |       |
| Preop temporary-LVAD    | 27 (14.1%)           |                          |                      |       |
| Days                    | 7.0 (4.0–11.0)       |                          |                      |       |
### Table 1. Cont.

| Baseline Characteristic | Overall (n = 192) | Profile 1–3 (n = 147) | Profile 4 (n = 45) | p   |
|-------------------------|-------------------|-----------------------|-------------------|-----|
| **Preop Bi-VAD Days**   | 2 (1.0%)          |                       |                   |     |
| **Preop Intubation Days** | 12.0 (10.0–14.0)   | 35 (18.2%)             | 0 (0.0%)          | <0.001 |
| **Preoperative Labs**   |                   |                       |                   |     |
| **Haemoglobin g/L**     | 11.0 (9.6–12.6)   | 10.6 (9.4–12.3)       | 12.1 (10.6–13.5)  | 0.040 |
| **Platelets count 10^9/L** | 209 (155–269)    | 211 (155–278)         | 201 (159–239)     | 0.759 |
| **D-dimer**             | 664 (277–1914)    | 824 (310–2322)        | 301 (202–552)     | 0.010 |
| **Bilirubin (mg/dL)**   | 0.95 (0.58–1.60)  | 1.05 (0.64–1.89)      | 0.74 (0.45–1.13)  | <0.001 |
| **AST (U/L)**           | 28 (20–42)        | 30 (21–46)            | 22 (16–30)        | 0.002 |
| **ALT (U/L)**           | 25 (17–41)        | 26 (18–46)            | 22 (15–35)        | 0.007 |
| **Amilasi (U/L)**       | 28 (19–60)        | 30 (20–67)            | 25 (16–36)        | 0.001 |
| **LAD (U/L)**           | 267 (192–421)     | 287 (211–450)         | 208 (160–273)     | 0.057 |
| **CRP (mg/L)**          | 19 (4–84)         | 32 (13–97)            | 3 (3–11)          | <0.001 |
| **Na (mmol/L)**         | 137 (134–140)     | 137 (134–139)         | 140 (136–142)     | 0.048 |
| **BNP**                 | 6267 (3555–12,460)| 8233 (3794–13,874)    | 3818 (1199–7560)  | 0.050 |
| **GFR (ml/min/m^2)**    | 64.0 (45.0–90.0)  | 68.0 (49.0–90.0)      | 56.0 (43.0–79.0)  | 0.182 |
| **Creatinine (mg/dL)**  | 1.26 (0.94–1.59)  | 1.24 (0.90–1.56)      | 1.39 (1.03–1.61)  | 0.567 |
| **Preoperative Echocardiogram** |                   |                       |                   |     |
| **EF (%)**              | 20 (17–26)        | 20 (17–24)            | 25 (20–29)        | 0.001 |
| **iLVEDV (mL/m^2)**     | 130 (110–157)     | 129 (106–157)         | 135 (114–162)     | 0.373 |
| **TAPSE (mm)**          | 15.0 (13.0–19.0)  | 15.0 (12.0–18.1)      | 18.2 (14.3–20.8)  | 0.771 |
| **sPAP (mmHg)**         | 43 (35–54)        | 43 (36–53)            | 44 (32–44)        | 0.758 |
| **RV FAC (%)**          | 31 (24–39)        | 29 (22–38)            | 36 (29–40)        | 0.002 |
| **TR ≥ moderate**       | 82 (42.7%)        | 64 (43.5%)            | 18 (40.0%)        | 0.732 |
| **MR ≥ moderate**       | 112 (58.3%)       | 87 (59.2%)            | 25 (35.6%)        | 0.731 |
| **AR ≥ moderate**       | 4 (2.1%)          | 3 (2.0%)              | 1 (2.2%)          | 0.941 |

Abbreviations: ALT, alanine transaminase; AR, aortic regurgitation; AST, aspartate transaminase; Bi-VAD, biventricular assist device; BNP, B-type natriuretic peptide; BSA, body surface area; BTC, bridge to candidacy; BTT, bridge to transplantation; CRP, C-reactive protein; CVVH, continuous venovenous hemofiltration; DCM, dilated cardiomyopathy; DT, destination therapy; ECMO, extracorporeal membrane oxygenation; EF, ejection fraction; GFR, glomerular filtration rate; ICD, implantable cardioverter defibrillator; IHD, ischemic cardiomyopathy; iLVEDV, indexed left ventricular end-diastolic volume; LDH, lactate dehydrogenase; LVAD, left ventricular assist device; MR, mitral regurgitation; RV FAC, right ventricle fractional area change; sPAP, systolic pulmonary artery pressure; TAPSE, tricuspid annular plane systolic excursion; TR, tricuspid regurgitation.

In-hospital mortality of the overall LVAD population was 25%. The main causes of in-hospital death were multi-organ failures in 50%, with almost 70% of them caused by RVF. Neurologic events occurred in 25% of cases. The overall Kaplan–Meier survival was 68% (62–75) at 12 months and 63% (56–71) at 24 months (Figure 1). Stratifying patients according to the INTERMACS profile in two groups, Profile 1–3 versus Profile 4, the overall survival (Figure 2) was significantly higher in the latter (61% vs. 91% survival at 1-year, log-rank = 0.014).
Table 2. LVAD implantation characteristics of overall (n = 192), INTERMACS Profile 1–3 (n = 147) and Profile 4 (n = 45) patients.

| LVAD Implantation                  | Overall (n = 192) | Profile 1–3 (n = 147) | Profile 4 (n = 45) | p   |
|------------------------------------|-------------------|-----------------------|--------------------|-----|
| Surgical access                    |                   |                       |                    |     |
| Full sternotomy                    | 110 (57.3%)       | 87 (59.2%)            | 23 (51.1%)         | 0.338 |
| Minimally invasive                 | 82 (42.7%)        | 60 (40.8%)            | 22 (48.9%)         | 0.390 |
| Outflow graft anastomosis          |                   |                       |                    |     |
| Ascending aorta                    | 154 (80.2%)       | 122 (83.0%)           | 32 (71.1%)         | 0.090 |
| Descending aorta                   | 27 (14.1%)        | 19 (12.9%)            | 8 (17.8%)          | 0.463 |
| Left subclavian artery             | 11 (5.7%)         | 6 (4.1%)              | 5 (11.1%)          | 0.134 |
| Associated procedures              | 25 (13.0%)        | 16 (10.9%)            | 9 (20.0%)          | 0.130 |
| Device Implantation                |                   |                       |                    |     |
| CPB                                | 121 (63.0%)       | 90 (61.2%)            | 31 (68.9%)         | 0.383 |
| ECMO                               | 31 (16.2%)        | 29 (19.7%)            | 2 (4.4%)           | 0.019 |
| Off-pump                           | 40 (20.8%)        | 28 (19.0%)            | 12 (26.7%)         | 0.297 |
| General anaesthesia                | 143 (74.5%)       | 104 (70.7%)           | 39 (86.7%)         | 0.033 |
| PVB analgesia                      | 48 (25.0%)        | 42 (28.6%)            | 6 (13.3%)          | 0.048 |
| Duration of intervention (min)     | 285 (240–370)     | 288 (240–366)         | 270 (235–400)      | 0.415 |
| Duration of CPB (min)              | 110 (82–150)      | 110 (87–152)          | 100 (67–136)       | 0.135 |

Abbreviations: CPB, cardiopulmonary bypass; ECMO, extracorporeal membrane oxygenator; PVB, paravertebral block.

Table 3. Postoperative outcomes and major adverse events of overall (n = 192), INTERMACS Profile 1–3 (n = 147) and Profile 4 (n = 45) patients.

| Postoperative Outcomes         | Overall (n = 192) | Profile 1–3 (n = 147) | Profile 4 (n = 45) | p  |
|--------------------------------|-------------------|-----------------------|--------------------|----|
| Intubation days                 | 1 (1–3)           | 1 (1–3)               | 1 (1–2)            | 0.117 |
| Tracheostomy                    | 15 (7.8%)         | 13 (8.8%)             | 2 (4.4%)           | 0.527 |
| Postop CVVH                      | 65 (33.9%)        | 57 (38.8%)            | 8 (17.8%)          | 0.006 |
| Days                            | 9.0 (4.0–17.0)    | 10.0 (4.0–22.5)       | 6.5 (3.5–10.0)     | 0.039 |
| RVF total                       | 89 (46.3%)        | 75 (51.0%)            | 14 (31.1%)         | 0.026 |
| Acute RVF                       | 63 (34.4%)        | 54 (36.7%)            | 9 (20.0%)          | 0.046 |
| Early-acute RVF                 | 28 (14.6%)        | 27 (18.4%)            | 1 (2.2%)           | 0.007 |
| Early-post-implant RVF          | 38 (19.8%)        | 32 (21.8%)            | 6 (13.3%)          | 0.563 |
| Chronic RVF                     | 30 (15.6%)        | 24 (16.3%)            | 6 (13.3%)          | 0.815 |
| RVAD implantation               | 42 (21.9%)        | 39 (26.5%)            | 3 (6.7%)           | 0.015 |
| Days                            | 10.0 (6.0–13.0)   | 9.5 (6.0–13.0)        | 12.0 (3.0–12.0)    | 0.823 |
| ECMO postop                     | 13 (6.8%)         | 12 (8.2%)             | 1 (2.2%)           | 0.306 |
| Days                            | 3.0 (2.0–6.0)     | 3.0 (1.3–6.8)         | 4                  | 0.954 |
| NO inhalation                   | 105 (54.7%)       | 82 (55.8%)            | 23 (51.1%)         | 0.609 |
Table 3. Cont.

| Major Adverse Events                  | Overall (n = 192) | Profile I–III (n = 147) | Profile IV (n = 45) | p     |
|--------------------------------------|-------------------|-------------------------|---------------------|-------|
| Major bleeding                       | 71 (37.0)         | 57 (38.8%)              | 14 (31.1%)          | 0.383 |
| Revision for bleeding                | 60 (31.2%)        | 50 (34.0%)              | 10 (22.2%)          | 0.147 |
| Cerebral event                       | 47 (24.5%)        | 35 (23.8%)              | 12 (26.7%)          | 0.583 |
| Non-fatal cerebral complications     | 28 (14.6%)        | 20 (13.6%)              | 8 (17.8%)           | 0.367 |
| Ischemic                             | 22 (11.5%)        | 17 (11.6%)              | 5 (11.1%)           | 0.233 |
| Haemorrhagic                         | 6 (3.1%)          | 3 (2.0%)                | 3 (6.7%)            | 0.187 |
| Fatal cerebral complications         | 19 (9.9%)         | 17 (11.6%)              | 2 (4.4%)            | 0.121 |
| Bowel complications                  | 26 (13.5%)        | 19 (12.9%)              | 7 (15.6%)           | 0.629 |
| Fatal bowel complications            | 5 (2.6%)          | 5 (3.4%)                | 0 (0.0%)            | 0.593 |
| Intra hospital documented infection  | 95 (49.5%)        | 80 (54.4%)              | 15 (33.3%)          | 0.017 |
| VAD infection                        | 2 (1.0%)          | 2 (1.4%)                | 0 (0.0%)            | 0.430 |
| VAD thrombosis                       | 15 (7.8%)         | 12 (8.2%)               | 3 (6.7%)            | 0.743 |
| Thrombolysis                         | 7 (3.6%)          | 7 (4.8%)                | 0 (0.0%)            | 0.203 |
| Driveline infection total            | 37 (19.3%)        | 28 (19.0%)              | 9 (20.0%)           | 0.504 |
| Within 6-months                      | 14 (7.3%)         | 12 (8.2%)               | 2 (4.4%)            | 0.525 |
| Over 6-months                        | 23 (12.0%)        | 18 (12.2%)              | 5 (11.1%)           | 0.925 |
| Postop-ICU (days)                    | 8.0 (4.0–18.0)    | 10.0 (5.0–20.0)         | 5.0 (3.0–15.3)      | 0.010 |
| In-hospital stay (days)              | 30.0 (20.0–45.0)  | 30.0 (20.5–52.5)        | 26.5 (20.0–41.5)    | 0.037 |
| 30-days death                        | 25 (13.0%)        | 22 (15.0%)              | 3 (6.7%)            | 0.206 |
| 90-days death                        | 43 (22.4%)        | 39 (26.5%)              | 4 (8.9%)            | 0.014 |
| In-hospital mortality                | 48 (25.0%)        | 45 (30.6%)              | 3 (6.7%)            | 0.001 |
| Cause of intra-hospital mortality    | <0.001            |                        |                     |       |
| Multiorgan failure                   | 26                | 26 (17.7%)              | 0 (0.0%)            |       |
| Neurologic                           | 12                | 10 (6.8%)               | 2 (4.4%)            |       |
| Bowel complications                  | 3                 | 2 (1.4%)                | 1 (2.2%)            |       |
| Sepsis                               | 7                 | 7 (4.8%)                | 0 (0.0%)            |       |
| Rehospitalization                    | 102 (53.1%)       | 76 (51.7%)              | 26 (57.8%)          | 0.648 |
| Number of rehospitalization          | 2 (1–4)           | 2 (1–4)                 | 2 (1–3)             | 0.996 |

Abbreviations: CVVH, continuous venovenous hemofiltration; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; LVAD, left ventricular assist device; NO, nitrous oxide, RVAD, right ventricular assist device; RVF, right ventricular failure.
3.2. Overall Results

The pertinent data are represented in Table 3. Profiles 1–3 patients showed a higher incidence of acute right ventricular failure (RVF) ($p = 0.046$), RVAD implantation ($p = 0.015$), and acute kidney failure requiring dialysis ($p = 0.006$). The most frequent adverse event observed was bleeding (37%), requiring at least one surgical revision in almost all cases (85%), followed by cerebral events in 24% of the population, mainly ischemic (60%), with 40% mortality. Bowel complications were present in 13% of the patients, but less than 3% died due to intestinal ischemia.

In-hospital mortality of the overall LVAD population was 25%. The main causes of in-hospital death were multi-organ failures in 50%, with almost 70% of them caused by RVF. Neurologic events occurred in 25% of cases. The overall Kaplan–Meier survival was 68% (62–75) at 12 months and 63% (56–71) at 24 months (Figure 1). Stratifying patients according to the INTERMACS profile in two groups, Profile 1–3 versus Profile 4, the overall survival (Figure 2) was significantly higher in the latter (61% vs. 91% survival at 1-year, log-rank = 0.014).

![Figure 1. Overall Survival. Patients were censored at time of transplant or last follow-up.](image1)

![Figure 2. Kaplan-Meier analysis of survival stratified by baseline INTERMACS patient profile.](image2)
3.3. Intention to Treat Analysis

3.3.1. Survival

According to the intention-to-treat analysis (Figure 3), actuarial survival was considerably higher in BTT compared to other implantation strategies (log-rank < 0.001).

Figure 3. Kaplan-Meier analysis of survival stratified by different implantation strategies.

In the BTT group (Figure 4), 12-month and 24-month survival was 83% (73–95) and 78% (64–94) in Profile 1–3 patients and 95% (87–100) and 86% (68–100) in Profile 4 patients, respectively (log-rank = 0.390). A competing analysis was conducted in the BTT cohort to evaluate the cumulative risk of a patient being alive, HT, or dead (Figure 5). One year after the implantation, 40% of the patients were transplanted, and less than 10% died. These percentages increased, after two years, to more than 62% of patients receiving an HT and an overall mortality rate of 13%.

In the BTC group (Figure 6), after a higher initial perioperative mortality rate in Profile 1–3 patients, Kaplan–Meier analysis showed comparable survival (log-rank = 0.120). 12-month and 24-month survival rates were respectively 54% (42–70) and 51% (39–68) in Profiles 1–3 patients and 88% (67–100) and 88% (67–100) in patients with Profile 4.

In the DT group (Figure 7), 1-year and 2-year survival were respectively 41% (28–60) and 33% (21–53) in Profiles 1–3 and 88% (73–100) and 81% (61–100) in Profile 4 (log-rank = 0.046).
Figure 3. Kaplan-Meier analysis of survival stratified by different implantation strategies.

Figure 4. Kaplan–Meier analysis of survival among INTERMACS Profile 1–3 and Profile 4 BTT patients.

Figure 5. Competing risk analysis in BTT patients: curves are used to represent the cumulative risk of a patient during the time of being alive, transplanted, or dead.

Figure 6. Kaplan–Meier analysis of survival among INTERMACS Profile 1–3 and Profile 4 BTC patients.
3.3.2. Major Adverse Events

In the BTT group, the need for RVAD support was higher in Profile 1–3 patients ($p = 0.042$). The incidence of other complications did not differ between groups. Only one death in the Profile 4 group was observed during the hospitalization ($12\%$ vs. $5\%$, $p = 0.674$) due to severe retroperitoneal hemorrhage and multi-organ failure.

In the BTC group, the in-hospital mortality rate in Profiles 1–3 was nearly quadrupled ($44\%$ vs. $12\%$, $p = 0.129$).

In the DT group, Profiles 1–3 patients showed a higher incidence of acute RVF ($p = 0.005$), RVAD implantation ($p = 0.026$), need for postoperative CVVH ($p = 0.034$), ICU length of stay ($p = 0.050$), and in-hospital mortality ($p = 0.012$).

4. Discussion

In order to understand the appropriate timing for LVAD implantation, several prospective studies compared patients with optimal medical management to those who received an LVAD [12,18–19].

The present investigation examines characteristics and outcomes from our single center LVAD experience. Based on different intention-to-treat (BTT, BTC, and DT) our cohort was stratified into two groups: “critically ill” and “elective” patients. The main findings were as follows:

(a) among BTT patients a similar survival regardless of the INTERMACS profile was observed, though a higher incidence of RVAD implantation was seen in the critically ill group.

(b) among BTC patients, slightly improved survival is seen in elective patients.

(c) among DT patients, higher survival is evident for elective patients.

LVAD therapy has been established in recent years as the therapy of choice in ESHF [1–4]. The INTERMACS profile represents a fundamental prognostic tool to guide clinical decision-making. Patients in cardiogenic shock have worse outcomes after LVAD.
3.3.2. Major Adverse Events

Major adverse events are reported in Table 3. In the BTT group, the need for RVAD support was higher in Profile 1–3 patients ($p = 0.042$). The incidence of other complications did not differ between groups. Only one death in the Profile 4 group was observed during the hospitalization (12% vs. 5%, $p = 0.674$) due to severe retroperitoneal hemorrhage and multi-organ failure.

In the BTC group, the in-hospital mortality rate in Profiles 1–3 was nearly quadrupled (44% vs. 12%, $p = 0.129$).

In the DT group, Profiles 1–3 patients showed a higher incidence of acute RVF ($p = 0.005$), RVAD implantation ($p = 0.026$), need for postoperative CVVH ($p = 0.034$), ICU length of stay ($p = 0.050$), and in-hospital mortality ($p = 0.012$).

4. Discussion

In order to understand the appropriate timing for LVAD implantation, several prospective studies compared patients with optimal medical management to those who received an LVAD [12,18,19].

The present investigation examines characteristics and outcomes from our single center LVAD experience. Based on different intention-to-treat (BTT, BTC, and DT) our cohort was stratified into two groups: “critically ill” and “elective” patients. The main findings were as follows:

(a) among BTT patients a similar survival regardless of the INTERMACS profile was observed, though a higher incidence of RVAD implantation was seen in the critically ill group.

(b) among BTC patients, slightly improved survival is seen in elective patients.

(c) among DT patients, higher survival is evident for elective patients.

LVAD therapy has been established in recent years as the therapy of choice in ESHF [1–4]. The INTERMACS profile represents a fundamental prognostic tool to guide clinical decision-making. Patients in cardiogenic shock have worse outcomes after LVAD implantation [18–20]. A correct indication remains the key to success and improving patient selection allows us to maximize the benefits of therapy. In a recent prospective study [12] on ambulatory patients with ESHF (INTERMACS profile 4–7), LVAD therapy was associated with improved quality of life and functional capacity compared with continued optimal medical management. However, according to the last EUROMACS report, only 23% of implantations were performed in INTERMACS Profiles 4 or higher [8].

The risk-benefit assessment of LVAD therapy and its related adverse events guide the clinician’s orientation. The “frequent flyer” patient is hanging by a thread with his apparent but labile hemodynamic compensation, often being delayed in common clinical practice by the cardiologist towards advanced surgical therapies. The absence of a timely consideration for advanced surgical therapies may limit the maximum benefit achievable or be contraindicated at the time of evaluation. According to our analysis, comparable survival observed in BTT patients, regardless of the INTERMACS profiles, can guide the decision-making and patient orientation, justifying the delay in the treatment in light of a risk-benefit assessment that takes into account not only mortality but also adverse events and LVAD-related complications. Our evidence supports that good long-term survival can be achieved with LVAD therapy as BTT and represents a reasonable alternative for critically ill patients in an era with a shortage of donors. This reassures patients and their families, who are often concerned about not being on time anymore for LVAD support when they drop into lower INTERMACS profiles. In detail, our results showed that patients bridged to transplantation have a better survival rate than those with other strategies, with less than a 10% one-year mortality rate. Compared to EUROMACS [8] and INTERMACS registries [6–8] our results were similar. Additionally, in our experience a BTT patient has a 40% probability to be transplanted at 12 months, reaching over 62% at 24 months [6,8]. Limiting the waiting list time for transplantation results in a lower incidence of adverse events [21–27]. Our strategy allows this subgroup group of patients to benefit from excellent
survival and to be in optimal condition for transplantation [25]. Although not significant, a trend towards a higher incidence of acute right ventricular dysfunction was noted in patients in INTERMACS Profile 1–3, with a greater proportion of patients requiring RVAD support. Despite this, in-hospital and overall survival were comparable.

As far as the BTC group is concerned, no differences in survival were observed. Unfortunately, the limited number of cases reduces the statistical power, and an adequate comparison is challenging. However, a slight trend towards better survival seems to be seen in elective patients. Some of these patients can be considered as a delayed referral with the progression of their ESHF that could have benefited from HT and/or LVAD implantation if evaluated in an earlier clinical phase. For this reason, advanced treatments should not be considered as the end point of therapeutic strategies when optimal medical management fails but as an integral part of the patient decision-making process.

Finally, DT patients showed a clearly different trend compared to the other groups. Preoperative unstable hemodynamic levels had an extremely poor prognosis in terms of complications and mortality. The rate of acute RVF was higher in the profile 1–3 patients, significantly contributing to the observed high in-hospital mortality. According to the latest INTERMACS registry, 47% of enrolled U.S. patients received an LVAD as DT treatment [6], and this percentage is expected to increase. We believe that this trend towards a broader DT indication is only admissible for elective patients.

These works provided key information on the risk-benefit balance to guide physician and patient orientation for elective LVAD therapy as a treatment of choice for ESHF. Our single center analysis aims to reinforce these considerations and support the clinician for the timely consideration of advanced treatments even in ambulatory patients.

5. Study Limitation

The main study limitation is its single center retrospective design. While this represents one of the greater LVAD series in Italy, as a single center, study the sample size may be limited. Despite our efforts to pursue LVAD therapy in elective patients, they often rejected the option of durable mechanical support in their early phase of disease and, as a result, the ambulatory group of our study was unbalanced. Moreover, by including more than ten years of experience with LVAD implantation, a learning curve has to be considered regarding patient management and postoperative management.

Three different devices were considered in our investigation. Although dissimilar rates of adverse events are described in the literature, no relevant differences in clinical outcomes were identified in our population in relation to the pump model. Finally, as we know that the implantation strategy is not an independent factor but relies on the clinical situation of the patient, we considered different INTERMACS profile in the same device strategy setting to limit this bias.

6. Conclusions

In conclusion, LVAD implantation in “elective” patients was associated with better survival and lower incidence of RVF and its complications. Our analysis showed a comparable survival in “critically ill” and “elective” BTT, while a significantly higher mortality rate was observed for “critically ill” DT patients. LVAD implantation in BTC patients must be considered before their conditions deteriorate.

Author Contributions: R.C.: Concept/design, Drafting article, Data collection, Data analysis/interpretation; J.B.: Concept/design, Critical revision of article; M.C.: Concept/design, Drafting article, Critical revision of article; O.B.: Data collection, Drafting article, Critical revision of article; V.T.: Approval of article; G.L.: Statistics, Data analysis/interpretation; D.B.: Statistics, Data analysis/interpretation; D.G.: Statistics, Data analysis/interpretation; C.C.: Critical revision of article; A.A.: Critical revision of article; T.B.: Concept/design Drafting article, Critical revision of article, Approval of article; G.G.: Critical revision of article, Approval of article. All authors have read and agreed to the published version of the manuscript.
Funding: This work was supported by the University of Padua grants: BIRD199570, BIRD204045, BIRD170215.

Institutional Review Board Statement: The local Institutional Review Board approved the study design, consent process, and review and analysis of the data (IBR number 48398/21).

Informed Consent Statement: Informed consent was obtained to participate in this study. Notably, the use of data for scientific and research purposes is already included in the surgical informed consent agreements. We also guarantee the respect of anonymity and professional secrecy and use the collected data and the statistical analysis solely for scientific purposes granted in accordance with the law in force (GDPR).

Data Availability Statement: The data that support the findings of this study are available from the corresponding author [T.B.] on request. The data are not publicly available due to restrictions because the information could compromise the privacy of research participants.

Conflicts of Interest: All authors have no conflict of interest or financial conflict to disclose.

References

1. Ponikowski, P.; Voors, A.A.; Anker, S.D.; Bueno, H.; Cleland, J.G.; Coats, A.J.; Falk, V.; González-Juanatey, J.R.; Ve, H.; Jankpwska, E.A.; et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur. Heart J. 2016, 37, 2129–2200. [CrossRef] [PubMed]

2. Yancy, C.W.; Jessup, M.; Bozkurt, B.; Butler, J.; Casey, D.E., Jr.; Drazner, M.H.; Fonarow, G.C.; Geraci, S.A.; Horwich, T.; Januzzi, J.L.; et al. American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013, 128, e240–e327. [CrossRef] [PubMed]

3. Crespo-Leiro, M.G.; Metra, M.; Lund, L.H.; Milicic, D.; Costanzo, M.R.; Filipatos, G.; Tsui, S.; Barge-Caballero, E.; De Jonge, N.; Frigerio, M.; et al. Advanced heart failure: A position statement of the Heart Failure Association of the European Society of Cardiology: Advanced heart failure: HFA position statement. Eur. J. Heart Fail. 2018, 20, 1505–1535. [CrossRef] [PubMed]

4. Truby, L.K.; Rogers, J.G. Advanced Heart Failure. JACC Heart Fail. 2020, 8, 523–536. [CrossRef]

5. Rose, E.A.; Gelijns, A.C.; Moskowitz, A.J.; Heitjan, D.F.; Stevenson, L.W.; Dembitsky, W.; Long, J.W.; Ascheim, D.D.; Tierney, A.R.; Levitan, R.G.; et al. Long-Term Use of a Left Ventricular Assist Device for End-Stage Heart Failure. N. Engl. J. Med. 2001, 345, 1435–1443. [CrossRef] [PubMed]

6. Kormos, R.L.; Cowger, J.; Pagani, F.D.; Teuteberg, J.J.; Goldstein, D.J.; Jacobs, J.P.; Higgins, R.S.; Stevenson, L.W.; Stehlik, J.; Atluri, P.; et al. The Society of Thoracic Surgeons Intermacs database annual report: Evolving indications, outcomes, and scientific partnerships. J. Heart Lung Transplant. 2019, 38, 114–126. [CrossRef]

7. Teuteberg, J.J.; Cleveland, J.C.; Cowger, J.; Higgins, R.S.; Goldstein, D.J.; Keebler, M.; Kirklin, J.K.; Myers, S.L.; Salerno, C.T.; Stehlik, J.; et al. The Society of Thoracic Surgeons Intermacs 2019 Annual Report: The Changing Landscape of Devices and Indications. Ann. Thorac. Surg. 2020, 109, 649–660. [CrossRef]

8. de By, T.M.M.H.; Mohacsi, P.; Gahl, B.; Zittermann, A.; Krabatsch, T.; Gustafsson, F.; Meyns, B.; Netuka, I.; Caliskan, K.; Castedo, E.; et al. The European Registry for Patients with Mechanical Circulatory Support (EUROMACS) of the European Association for Cardio-Thoracic Surgery (EACTS); Second report. Eur. J. Cardio Thorac. Surg. 2018, 53, 309–316. [CrossRef]

9. Potapov, E.V.; Antonides, C.; Crespo-Leiro, M.G.; Combes, A.; Färber, G.; Hannan, M.M.; Kukucka, M.; De Jonge, N.; Loforte, A.; Lund, L.H.; et al. 2019 EACTS Expert Consensus on long-term mechanical circulatory support. Eur. J. Cardio Thorac. Surg. 2019, 56, 230–270. [CrossRef]

10. Casarotto, D.; Botti, T.; Gambino, A.; Testolin, L.; Gerosa, G. The last to die is hope: Prolonged mechanical circulatory support with a Novacor left ventricular assist device as a bridge to transplantation. J. Thorac. Cardiovasc. Surg. 2003, 125, 417–418. [CrossRef]

11. Apostolo, A.; Paolillo, S.; Contini, M.; Vignati, C.; Tarzia, V.; Campodonico, J.; Mapelli, M.; Massetti, M.; Bejko, J.; Righini, F.; et al. Comprehensive effects of left ventricular assist device speed changes on alveolar gas exchange, sleep ventilatory pattern, and exercise performance. J. Heart Lung Transplant. 2018, 37, 1361–1371. [CrossRef] [PubMed]

12. Estep, J.D.; Starling, R.C.; Horstmanshof, D.A.; Milano, C.A.; Selzmann, C.H.; Shah, K.B.; Loewe, M.; Moszami, N.; Long, J.W.; Stehlik, J.; et al. ROADMAP Study Investigators. Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients: The ROADMAP Study 2-Year Results. JACC Heart Fail. 2017, 5, 518–527.

13. Kormos, R.L.; Antonides, C.F.; Goldstein, D.J.; Cowger, J.A.; Starling, R.C.; Kirklin, J.K.; Rame, J.E.; Rosenthal, D.; Mooney, M.L.; Caliskan, K.; et al. Updated definitions of adverse events for trials and registries of mechanical circulatory support: A consensus statement of the mechanical circulatory support aca-demic research consortium. J. Heart Lung Transplant. 2020, 39, 735–750. [CrossRef] [PubMed]
14. Carrozzini, M.; Bejko, J.; Guariento, A.; Rubino, M.; Bianco, R.; Tarzia, V.; Gregori, D.; Bottio, T.; Gerosa, G. Minimally Invasive Implantation of Continuous Flow Left Ventricular Assist Devices: The Evolution of Surgical Techniques in a Single-Center Experience. *Artif. Organs* **2018**, *43*, E41–E52. [CrossRef]

15. Carrozzini, M.; Bejko, J.; Gerosa, G.; Bottio, T. Bilateral mini-thoracotomy approach for minimally invasive implantation of HeartMate 3. *Artif. Organs* **2018**, *43*, 593–595. [CrossRef]

16. Bottio, T.; Bejko, J.; Falasco, G.; Bortolussi, G.; Gallo, M.; Tarzia, V.; Gerosa, G. Less-invasive off-pump ventricular assist device implantation in regional paravertebral analgesia. *J. Artif. Organs* **2014**, *17*, 275–277. [CrossRef]

17. R Development Core Team. *R: A Language and Environment for Statistical Computing*; R Foundation for Statistical Computing: Vienna, Austria, 2020. Available online: https://www.R-project.org/ (accessed on 11 August 2021).

18. Kittleson, M.M.; Shah, P.; Lala, A.; McLean, R.C.; Pamboukian, S.; Horstmanshof, D.A.; Thibodeau, J.; Shah, K.; Teuteberg, J.; Gilotra, N.A.; et al. INTERMACS profiles and outcomes of ambulatory advanced heart failure patients: A report from the REVIVAL Registry. *J. Heart Lung Transplant.* **2019**, *38*, 16–26. [CrossRef]

19. Ambardekar, A.V.; Kittleson, M.M.; Palardy, M.; Mountis, M.M.; Forde-McLean, R.C.; DeVore, A.D.; Pamboukian, S.V.; Thibodeau, J.T.; Teuteberg, J.J.; Cadaret, L.; et al. Outcomes with ambulatory advanced heart failure from the Medical Arm of Mechanically Assisted Circulatory Support (MedaMACS) Registry. *J. Heart Lung Transplant.* **2018**, *38*, 408–417. [CrossRef]

20. Dell’Aquila, A.M.; Schneider, S.R.; Stypmann, J.; Ellger, B.; Redwan, B.; Schlarb, D.; Martens, S.; Sindermann, J.R. Survival results after implantation of intrapericardial third-generation centrifugal assist device: An INTERMACS-matched comparison analysis. *Artif. Organs* **2014**, *38*, 383–390. [CrossRef]

21. Stepanenko, A.; Potapov, E.V.; Jurmann, B.; Lehmkuhl, H.B.; Dandl, M.; Siniawski, H.; Drews, T.; Hennig, E.; Kaufmann, F.; Jurmann, M.J.; et al. Outcomes of elective versus emergent permanent mechanical circulatory support in the elderly: A single-center experience. *J. Heart Lung Transplant.* **2010**, *29*, 61–65. [CrossRef]

22. Caruso, R.; Verde, A.; Cabiati, M.; Milazzo, F.; Boroni, C.; Del Ry, S.; Parolini, M.; Vittori, C.; Paino, R.; Martinelli, L.; et al. Association of pre-operative interleukin-6 levels with Interagency Registry for Mechanically Assisted Circulatory Support profiles and intensive care unit stay in left ventricular assist device patients. *J. Heart Lung Transplant.* **2012**, *31*, 625–633. [CrossRef] [PubMed]

23. Trivedi, J.R.; Cheng, A.; Singh, R.; Williams, M.L.; Slaughter, M.S. Survival on the heart transplant waiting list: Impact of continuous flow left ventricular assist device as bridge to transplant. *Ann. Thorac. Surg.* **2014**, *98*, 830–834. [CrossRef] [PubMed]

24. Carrozzini, M.; Bejko, J.; Gambino, A.; Tarzia, V.; Lanera, C.; Gregori, D.; Gerosa, G.; Bottio, T. Results of new-generation intrapericardial continuous flow left ventricular assist devices as a bridge-to-transplant. *J. Cardiovasc. Med.* **2018**, *19*, 739–747. [CrossRef] [PubMed]

25. Carrozzini, M.; Bottio, T.; Caraffa, R.; Bejko, J.; Bifulco, O.; Guariento, A.; Lombardi, C.M.; Metra, M.; Azzolina, D.; Gregori, D.; et al. Impact of Continuous Flow Left Ventricular Assist Device on Heart Transplant Candidates: A Multi-State Survival Analysis. *J. Clin. Med.* **2022**, *11*, 3425. [CrossRef] [PubMed]

26. Bifulco, O.; Bottio, T.; Caraffa, R.; Carrozzini, M.; Guariento, A.; Bejko, J.; Fedrigo, M.; Castellani, C.; Toscano, G.; Lorenzoni, G.; et al. Marginal versus Standard Donors in Heart Transplantation: Proper Selection Means Heart Transplant Benefit. *J. Clin. Med.* **2022**, *11*, 2665. [CrossRef]

27. Bejko, J.; Toto, F.; Gregori, D.; Gerosa, G.; Bottio, T. Left ventricle assist devices and driveline’s infection incidence: A single-centre experience. *J. Artif. Organs* **2017**, *21*, 52–60. [CrossRef]